Clinical Trials Directory

Trials / Sponsors / Five Prime Therapeutics, Inc.

Five Prime Therapeutics, Inc.

Industry · 11 registered clinical trials.

StatusTrialPhaseStarted
TerminatedFPT155 in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Phase 12018-10-18
CompletedA Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Juncti
Gastric Cancer
Phase 22018-09-14
TerminatedFPA150 in Patients With Advanced Solid Tumors
Breast Cancer, Ovarian Cancer, Endometrial Cancer
EARLY_Phase 12018-03-27
CompletedA Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer
Gastrointestinal Cancer, Gastrointestinal Cancer Metastatic, Gastric Cancer
Phase 12017-11-30
CompletedStudy of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Advanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer
Phase 12015-09-08
CompletedStudy of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cel
Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor
Phase 1 / Phase 22015-06-01
CompletedOpen-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
Advanced Solid Tumors, Gastric Cancer, Transitional Cell Carcinoma of the Bladder
Phase 12014-11-01
TerminatedPhase 1 Single and Multiple Dose Study of FPA008 in Healthy Volunteers and Rheumatoid Arthritis Subjects
Healthy, Rheumatoid Arthritis
Phase 12013-10-01
WithdrawnStudy of FP-1039 in Subjects With Endometrial Cancers
Endometrial Cancers With FGFR2 Mutations
Phase 22011-01-01
CompletedSafety Study of FP-1039 To Treat Cancer
Advanced Cancer
Phase 12008-07-01
No Longer AvailableAn Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer
Recurrent Bladder Cancer
——